Winter Arrhythmia School invites you to submit your abstract before November 15th, 2015!
Deadline: November 15th, 2015
International Winter Arrhythmia School (IWAS) is accepting abstracts for the 13th IWAS. The subject should be related to Channelopathy, Sudden death and Syncope.
The registration fee for authors who have been selected for either a poster display or oral presentation will be waived. The 3 best abstracts will be recognized with IWAS awards.
Please complete and e-mail the form below to firstname.lastname@example.org
1) Objective: clearly state the purpose of the abstract
2) Methodology: describe your selection of observations or experimental subjects clearly.
3. Summary of result: present your results in a logical sequence
4. Conclusion: emphasise new and important aspects of the study (perhaps as a discussion section) and the conclusions that are drawn from them
• The Scientific Committee will review all submitted abstracts
• Notification of abstract acceptance will be sent to all authors by December 10th, 2015
If you have questions regarding the abstract submission process, please contact: email@example.com or call at (416) 480-6100 ext. 7537
Queen’s University – School of Medicine
Background: Post coronary artery bypass graft atrial fibrillation (PCAF) is associated with increased morbidity, mortality, and system costs. Few studies explored obstructive sleep apnea (OSA) as a risk factor for PCAF. We aimed to systematically review and synthesize the evidence associating OSA with PCAF.
Methods: We conducted a search in MEDLINE, Embase, Google Scholar, Web of Science, abstracts, conference proceedings, and reference lists until June 2014. Eligible studies were English, conducted in humans, and assessed OSA with polysomnography or a validated questionnaire. Two reviewers independently selected studies, with disagreement resolved by consensus. Piloted forms were used to extract data and assess risk of bias.
Results: Five prospective cohort studies were included (n = 642). There was agreement in study selection (κ 0.89, 95% confidence interval [CI] 0.75 to 1.00). OSA was associated with a higher risk of PCAF (odds ratio [OR] 1.86, CI 1.24 to 2.80; p = 0.003; I2 = 35%). We conducted three subgroup analyses. The associations increased for data that used polysomnography to assess OSA (OR 2.34, CI 1.48 to 3.70), when severe OSA was included from one study (OR 2.59, CI 1.63 to 4.11), and when adjusted analyses were pooled (OR 2.38, CI 1.57 to 3.62; p <0.001 in all), with no detected heterogeneity in any subgroup analysis (I2 <0.01% in all). Discussion: We found OSA to increase the odds of PCAF by approximately two-fold. Despite the multifactorial risk for PCAF, we are confident in the validity of the unadjusted analyses given their similarity to the adjusted analysis. We did not identify any investigations assessing the effectiveness of OSA management strategies in reducing PCAF and other complications in this population, making it an appealing future research topic. Conclusions: OSA was shown to be a strong predictor of PCAF. Future research efforts should aim to assess the effectiveness of OSA identification and management strategies in reducing PCAF and other complications in this population. [/su_spoiler] [su_spoiler title="Feasibility and Safety of Using Mechanic and Magnetic Robotic Systems for EGM-Guided AF Ablation with Near Zero Radiation: A Pilot Study" style="fancy" icon="chevron"] Authors: Atsuhiko Yagishita, MD; Harish Manyam, MD; Samer De Oliveira, MD; Alvaro Manrique, MD; Michael Arredondo, MD; Harikrishnan Santhakumari, MD; Ivan Cakulev, MD; Judith Mackall, MD; Mauricio Arruda, MD Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University, School of Medicine, Cleveland, Ohio, USA
Purpose: This pilot study was designed to assess the feasibility and safety of using the Stereotaxis and the AmigoTM Remote Catheter System (RCS) as a non-fluoroscopic approach for EGM-guided atrial fibrillation (AF) ablation.
Methods: This prospective study enrolled 11 consecutive patients presenting for radiofrequency (RF) catheter ablation of AF. Group 1. The initial 3 patients underwent 3-D electroanatomic voltage mapping while creating LA and PV antra geometry. This was obtained by roving a custom, bidirectional multi-electrode circular catheter remotely via the Amigo RCS. Subsequently, PV electrical isolation (PVI) and adjunctive ablation was performed by remote RF delivery via the Stereotaxis magnetic system. This phase was designed to allow the operator to become familiar with the Amigo remote navigation and fluoroscopy was allowed as needed. Group 2. The subsequent 8 patients underwent the same procedure to test the following hypothesis: “A fully robotic EGM-guided AF ablation can be performed without or minimal radiation exposure”.
Results: All 11 patients underwent successful robotic EGM-guided PVI, scar substrate and CTI ablation, as needed using the Stereotaxis and the Amigo RCS systems. In all patients in Group 2, LA and RA mapping (22 ± 4 min.) and ablation (108 ± 31 min.) were performed without fluoroscopic. The mean fluoroscopic time and total radiation exposure (μGym2) was 49.2 ± 21.6 vs. 4.6 ± 2.9 min., and 28602.9 ± 22695.5 vs. 2386.2 ± 1101.6 μGym2 for Group 1 and Group 2, respectively (P < 0.001). There were no complications and AF recurred in 1 patient during short-term follow-up (99-126 days). Conclusion: This pilot study suggests that a fully robotic EGM-guided AF ablation and adjunctive ablation can be performed safely and with minimal radiation exposure. Table 1. Patient characteristics, procedure and radiation exposure
Authors: Labonny Biswas, Robert Xu, Philippa Krahn, Sebastian Ferguson, Roey Flor, Samuel Oduneye, Mihaela Pop, Graham Wright
Sunnybrook Research Institute
Our aim is to develop a robust visualization platform for MRI-guided cardiovascular interventions and to test it extensively in preclinical studies prior to integration into a clinical workflow. Here we present the capabilities of the platform useful for electrophysiology (EP) interventions and data analysis.
Vurtigo is an advanced visualization tool for image-guided therapies. It can load anatomical roadmaps and segmentations and overlay them with real-time information from the MRI scanner, including imaging planes and tracked devices. Voltage information recorded from MR EP catheters can be read and processed with catheter coordinates to display voltage amplitude and isochronal maps on heart chamber meshes. Additionally, myocardial tissue characterization maps segmented from delayed-enhancement MR images can be overlaid within the scene to help guide ablation therapies.
Summary of Results:
We have successfully developed and used Vurtigo in various EP studies employing healthy and pathologic swine models. Voltage maps and position readings from clinical fluoroscopic catheters were displayed as surface meshes and fused with MR information. MR-guided catheter tip positions generated in Vurtigo produced lower displacement errors of 2.1±1.1 mm, compared to 4.8±2.0 mm from a conventional clinical mapping system. Bipolar voltage maps recorded with either a conventional electro-anatomical system or an MR-guided EP system corresponded very well with the potential VT substrate and endocardial scar location identified in MR images. Lastly, registration and fusion of isochronal maps with 3D MR-derived meshes for modelling and simulations of electrical wave propagation were implemented.
Vurtigo has been instrumental in preclinical EP studies of ventricular arrhythmia and ablation and shows promise for improved visualization of EP interventions to be translated to the clinic. Ongoing development on the platform includes registration of segmentation models obtained from MR with real-time fluoroscopy, correction of roadmaps due to respiratory motion, and exploration of novel mechanisms of interaction for scanner control.
Authors: Byron H Gottschalk, Josep Brugada, Pedro Brugada, Daniel D Anselm, Arthur AM Wilde, Pablo A Chiale, Andres R Perez-Riera, Marcelo V Elizari, Antoni Bayes de Luna, Pieter Postema, Andrew Krahn, Hanno L Tan, Adrian Baranchuk
Objective: Brugada Phenocopies (BrP) are clinical entities characterized by ECG patterns that are identical to true congenital Brugada Syndrome (BrS), but are elicited by various clinical circumstances. The idea that both patterns are identical has never been tested. The aim of our study was to determine whether world experts on BrS were able to reliably distinguish between the patterns of BrS and BrP.
Methods: Six ECGs from genetically confirmed BrS and six ECGs from confirmed BrP were included in the study. Surface 12-lead ECGs were scanned, saved in JPEG format at 150-300 DPI, and sent to 10 experts on BrS for rating (no clinical history provided). Raters were asked to label each case as a Brugada ECG pattern or non-Brugada ECG pattern by sight alone.
Results: The average accuracy rate for each observer versus the true value was 43% for BrP and 63% for BrS suggesting distinction between BrP and BrS patterns is close to as good as chance. Kappa coefficients calculated individually for each rater, defined as the chance-corrected proportion correct, had an average of 0.05, indicating there is essentially no better than chance agreement between raters and the true diagnosis.
Conclusions: Experts on BrS were unable to distinguish between the ECG patterns of BrS and BrP. This information supports the contention that the two patterns are identical and that further workup is required to differentiate the two conditions.
Ribas Sebastian, Healey Jeff S, Connolly Stuart J, Morillo Carlos A
Arrhythmia Service & Hamilton Atrial Fibrillation Reference Centre, Hamilton Health Sciences, McMaster University
Introduction: Direct oral anticoagulants (DOACs) are a treatment alternative to warfarin for stroke prevention in patients with atrial fibrillation (AF). Limited data is available regarding real world usage and safety of DOACs (Dabigatran, Rivaroxaban and Apixaban) in the setting of electrical cardioversión (ECV) for atrial tachyarrrhytmias.
Methods: Retrospective analysis of all patients booked for ECV at our Cardiac Arrhythmia Unit between January 2012 and September 2014. Inclusion criteria included patients with non-valvular AF or atrial flutter of >48h taking any oral anticoagulant. The main exclusión criteria were severe mitral valve stenosis and mechanical heart valves. Patients were followed for a minimun of 42 days after ECV to evaluate thrombo-embolic (TE) events defined as (stroke, systemic embolism, LAA thrombus) and bleeding events. Of 390 patients, 379 were included and 18 (4.7%) were lost to follow-up.
Results: 123 (32.4%) patients recieved warfarin and 256 (67.5%) DOACs (59% Dabigatran, 27.3% Rivaroxaban, 13.7% Apixaban). Mean age 62.1 ± 13.1, 71% male without differences between both groups. 20 (7.8%) patients did not undergo ECV in the DOAC goup (sinus rhythm pre-ECV) and 18 (14.6%) in warfarin group (55.5%) due to inadequate anticoagulation or thrombo in left atrium).The mean CHADS2 Score was higher in warfarin group 1.87 ± 1.4 vs 1.23 ± 1.0 p=<0.01 . TE events occurred in 4 (1%) patients: 0 in DOACs and 4 (3.2%) in warfarin group p=<0.01. Major bleeding events ocurred in 2 (0.6%) patients: 1 (0.4%) DOAC and 1 (0.8%) warfarin group p=0.52. Conclusions: At an academic tertiary hospital DOACs are used in almost 70%patients undergoing ECV, and in lower thrombo-embolic risk population. Adverse events were rare and DOACs appear to be a safe and effective alternative to warfarin in this setting. [/su_spoiler] [su_spoiler title="Real-time Lesion Characterization and Visualization for Image-guided Cardiac Ablation Therapy" style="fancy" icon="chevron"] Cristian A. Linte Biomedical Engineering & Center for Imaging Science, Rochester Institute of technology, Rochester NY USA 14467
Purpose: In addition to accurate intracardiac catheter navigation, successful treatment via ablation also requires effective intra-operative feedback about the quality of the delivered ablation lesion. To date little effort has been channeled toward the integration of ablation models into the clinical workflow for online lesion characterization and visualization. We describe a fast and reasonably accurate ablation model that facilitates the visualization and characterization of the induced ablation lesion in real time.
Methods: Our proposed ablation model computes the tissue temperature distribution and induced lesion according using an image-based implementation. Several image volumes updated every computational cycle are used to evaluate tissue temperature, induced tissue damage, and lesion progression. As tissue damage is a function of both temperature and time, we estimate tissue injury using Cumulative Exposure –the area under the temperature – time curve. Cumulative exposure beyond cell-death temperature (55C) for 5s or longer is classified as irreversible damage and the corresponding voxels in the tissue exposure volume are digitally marked in the tissue lesion volume.
Results: We assessed the accuracy of the model against the of two other tissue injury criteria previously explored. The former criterion is the volume enclosed by the 50C isothermal surface, shown to be consistent with the non-viable tissue region post-ablation. The former criterion characterizes tissue injury (Ω(t)) via an empirical exponential relationship that renders tissue injury as reversible for Ω < 0.5 and irreversible for Ω ≥ 1. The critical cell-death temperature for heart tissue was shown to be 58C for 1s exposure, supporting our cumulative exposure threshold of 55C and above for 5s or longer. Moreover, the size of the irreversibly-damaged tissue region predicted via Cumulative Exposure was within 1 mm of the diameter of the irreversible region predicted by the other two criteria. Conclusion: We described a real-time image-based model for predicting, assessing and visualizing the induced tissue injury and lesion development during image-guided cardiac ablation therapy. Results have demonstrated agreement within 1 mm between the tissue characterized irreversibly injured via the proposed model and the region deemed irreversible by two other tissue damage criteria [/su_spoiler] [su_spoiler title="Antiarrhythmic therapy post-ablation to reduce atrial fibrillation recurrence: a meta-analysis" style="fancy" icon="chevron"] Authors: Goldenberg G, Burd D, Lodzinski P, Stabile G, Udell J, Shurrab M, Crystal E. Sunnybrook Hospital
Three months of empirical antiarrhythmic drug (AAD) therapy after atrial fibrillation ablation (AFA) is common to prevent early AF recurrence with limited data to support this practice.
OBJECTIVE: To perform a meta-analysis of published controlled trials comparing temporary AAD therapy after AFA with standard care in patients after AFA. The primary outcome was recurrence of arrhythmia. A subgroup analysis stratified patients by durations of follow-up at 6 months.
RESULTS: Seven trials were included; six were randomized and one was a retrospective controlled study. Among 1245 patients, 763 (61.3%) had paroxysmal AF, and 318 (25.5%) had persistent AF. In total, 747 patients were treated with AADs and 498 patients served as a control group (no AA therapy). Various class IC-III antiarrhythmics were used. Length of AAD administration varied between 6 weeks immediately following AFA to 3 months. The follow-up duration ranged from 1.5 to 12 months. Among AAD treated patients, the recurrence of arrhythmia rate was 33.4% vs. 39.5% in control patients (odd ratio 0.75, 95% CI 0.54-1.03, P=0.08)., Subgroup analysis revealed that among patients followed for 6 months or longer after AFA, AAD treated patients had an arrhythmia recurrence rate of 32.9% compared with 45.1% among control (odds ratio 0.55, 95% CI 0.33-0.91, P=0.02). However, no significant heterogeneity was noted compared with patients followed for less than 6 months (I2= 39%, P=0.18).
Temporary antiarrhythmic therapy after AFA appears to be effective in reducing delayed (6 months or longer) recurrence of AF.
University of Illinois College of medicine
Objective: The primary objective of study is to compare the efficacy of manual and robotic catheter ablation in treatment of atrial fibrillation in terms of acute and chronic success. This study also compares the procedure time and radiation exposure between the two types of procedures.
Methodology: A retrospective data analysis was done for 71 patients who underwent catheter ablation, either manual or robotic, for drug refractory symptomatic atrial fibrillation at our community hospital. Patients were either assigned to manual ablation group (n=34) or robotic ablation group (n=37), based on clinician preference. The Sensei X (Hansen Medical, Inc.) was the robotic tool employed.
Summary of results: When defined as maintenance of sinus rhythm, the success rate for robotic ablation is equivalent to that for manual ablation at 6 months after procedure, 54% vs. 61%, in this cohort with a predominance of persistent atrial fibrillation. The procedure time was similar, but the radiation exposure in robotic ablation is less compared to manual ablation, 29 vs. 36 minutes fluoroscopy time.
Conclusions: An early result of this study suggests that robotic catheter ablation is as efficacious as manual catheter ablation for treatment of drug refractory atrial fibrillation at our center. Moreover, robotic catheter ablation reduces radiation exposure, and sitting posture to perform robotic manipulation reduces operator fatigue. This study supports the use of robotic catheter ablation for atrial fibrillation in a community hospital setting.
Authors: Krahn Philippa, Venkat Ramanan, Kevan Anderson, Jennifer Barry, Bonny Biswas, Robert Xu, Nicolas Yak, Sheldon Singh, Mihaela Pop, Graham A. Wright
Sunnybrook Research Institute
MRI is a non-invasive method for visualizing RF ablation lesions. In particular, intrinsic-contrast MRI (without contrast agent injection) may be a practical method to evaluate the size and properties of lesions. This study aims to characterize inherent MR properties of ablation lesions to contribute to the understanding of tissue structure within minutes of ablation.
4 endocardial lesions were created in 2 healthy pigs. An MR-compatible catheter was navigated within the left ventricle using real-time MR guidance. At the ablation site, 40W was delivered for 45-60s. An inversion-recovery steady-state free precession (IR-SSFP) intrinsic-contrast MR technique was repeated to visualize lesion cores at several time points. In an additional set of 2 pigs, 2 ablations were followed by T2-weighted MRI.
SUMMARY OF RESULTS
In the first 2 pigs, intracardiac electrogram (EGM) amplitudes decreased by 45±20% during ablation. We inferred from these signals that the tissue had been burned sufficiently to cause necrosis. Gross pathology and histology (stains) later confirmed this assessment. IR-SSFP images showed the necrotic lesion cores <5 minutes after ablation. within 5 time intervals (0-10, 10-30, 30-50, 50-70, and 70-100 minutes) post-ablation, lesion cnr relative to surrounding myocardium was consistent (mean 1.9±0.7) with no statistically significant difference between (p>0.5). The size and shape of lesions visualized in IR-SSFP images matched with those in gross pathology slices. Lesions visualized with T2-weighted imaging depicted edema <25 minutes after ablation. discussion ablation-induced structural changes in tissue are responsible for lesion visualization intrinsic-contrast mri. stable contrast suggests that the core of thermal damage is established immediately upon ablation and its mr properties do not change markedly during following 100 minutes. further studies will additionally focus on investigation edema development over time, may include pacing threshold measurements to more directly probe extent damage. conclusions mri a promising option rapid assess lesions. this method also avoids delay timing complications associated with agent-based imaging techniques. an tool consistently highlights lesions at various times procedure be extremely valuable. [>Division of Cardiology – Department of Medicine – Queen’s University
Background: Advanced interatrial block (aIAB) on the surface electrocardiogram (ECG), defined as a p-wave duration ≥ 120 ms with biphasic (±) morphology in inferior leads, is frequently associated with atrial fibrillation (AF). The aim of this study was to determine whether pre-operative aIAB could predict new-onset AF in patients with severe congestive heart failure (CHF) requiring cardiac resynchronization therapy (CRT).
Methods: Retrospective analysis of consecutive patients with CHF and no prior history of AF undergoing CRT for standard indications. A baseline 12-lead ECG was obtained prior to device implantation and analyzed for the presence of aIAB. ECGs were scanned at 300 DPI and maximized x 8. Semiautomatic calipers were used to determine p-wave onset and offset. The primary outcome was the occurrence of AF identified through analyses of intracardiac electrograms on routine device follow-up.
Results: Ninety-seven patients were included (74.2% male, left atrial diameter 45.5±7.8 mm, 63% ischemic). Mean P-wave duration was 138.5 ± 18.5 ms and 37 patients (38%) presented aIAB at baseline. Over a mean follow-up of 32±18 months, AF was detected in 29 patients (30%) and the incidence was greater in patients with aIAB compared to those without it (62% vs 28%; p <0.003). aIAB remained a significant predictor of AF occurrence after multivariate analysis (OR 4.1; 95% CI 1.6-10.7; p 0.003). Conclusion: The presence of aIAB is an independent predictor of new-onset AF in patients with severe CHF undergoing CRT. [/su_spoiler] [su_spoiler title="Remote magnetic navigation versus manually controlled catheter ablation of right ventricular outflow tract ventricular arrhythmias: A retrospective single center experience " style="fancy" icon="chevron"] Authors: Ayelet Shauer, MD, Jorge Palazzolo, MD, Mohammed Shurrab, MD, Ilan Lashevsky, MD, Sheldon Singh, MD, Irvin Tiong, MD, David Newman, MD and Eugene Crystal, MD. Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Remote magnetic navigation (RMN) has been introduced as an alternative to manual catheter control (MCC) radiofrequency ablation of right ventricular outflow tract (RVOT) arrhythmia. The comparative data to support RMN approach are limited; especially for the novel platform of RMN EpochTM.
OBJECTIVE: The aim of this study was to retrospectively evaluate the clinical and procedural outcomes in a cohort of patients undergoing RVOT PVCs/VT ablation procedures using RMN vs. MCC.
Thirty seven consecutive patients (mean age: 53, range 23-84 years, 16 females) with RVOT PVCs/VT, LVEF 57±9 and RVEF 53±7, underwent ablation and were included (RMN: 20 patients vs MCC: 17 patients). Endocardial mapping using CARTOXPTM or CARTO3 (Biosense Webster) was used in 6/20 (30%) in RMN group and 6/17 (35%) in MCC group; EnSiteTM NavXTM (St. Jude Medical) system was used in the rest of the cohort. NiobeTM II EpochTM platform (Stereotaxis Inc, St. Louis, MO) was used for RMN approach.
The procedural time was 109±66 min in the RMN group and 109±71 min in MCC (p=0.98). However, total fluoroscopic time was 10.0±7.1 min in RMN vs. 17.6±8.8 in MCC group (p=0.01). Total ablation energy application time was 9.4±5.2 min in RMN vs. 9.7±6.0 min in RCC, p=0.88). There were no complications in the RMN group and 3 cardiac tamponade events in the MCC group (p= 0.09). Acute procedural success rate was 75% in RMN vs 76% in MCC group (p=1.0). Long term success was available for 32 of the 37 patients. The success rate during median follow up of 10.2±5.9 months was 63% in both groups (P=1.0)
RVOT arrhythmia ablation using novel platform of RMN demonstrates lower fluoroscopic time and a trend for lower cardiac tamponade rate than ablation with manual approach. Both techniques demonstrate similar success rates.
Authors: Suzette Turner RN(EC),
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
It is estimated that over 120, 000 Canadians are living with cardiac implantable electronic devices (CIED). These include a broad spectrum of devices that have the ability to maintain rhythm, provide cardiac resynchronization therapy, and/or prevent sudden cardiac death. Approximately 15 000 CIED are implanted in Canada every year with an associated 1- 2% risk of infection. More than 70% of CIED patients are over the age of 65, and more than 75% of them had 1 or more coexisting co-morbidities. Based on the literature, device infection could be the most important complication as treatment is complex and complete infection eradication may require total system removal due to potential for endocarditis and sepsis. Besides causing morbidity and even death, infection is associated with significant financial cost for patients and the health care system. As is known with all complications, prevention is the key and as such this poster will highlight current management strategies. This poster will also outline CIED infection from diagnosis to treatment including risk factor identification as well as the identification of emerging preventative and treatment strategies.
The performance of magnetic resonance imaging (MRI) is contraindicated in the presence of conventional cardiac devices. However, given the increasing number of indications for MRI and the growing number of device implants, MRI-conditional devices have been developed. The safe performance of MRI in patients with these select devices requires careful verification of the compatibility of these technologies.
Our objective was to develop a rigorous screening protocol to ensure the correct compatibility has been verified before MRI is performed. A review of the literature, clinical trial recommendations, and screening protocols at health centres currently performing MRIs in this patient population was conducted.
Interprofessional discussions led to the development of an expert consensus screening protocol. Very few centers nationally are performing MRIs on patients with conditional cardiac devices. Screening protocols are not standardized, and there is limited experience using them long term to ensure safety verification. Protocol development and adherence requires collaboration with various healthcare team members, including the radiologist, electrophysiologist, treating physician, manufacturer, management, nursing, technologist, and patient. Lack of standardized screening protocols has traditionally led to MRI refusal in patients with these cardiac devices.
Standardized screening protocols are required to ensure patients with conditional cardiac devices have safe access to MRI imaging. A prospective evaluation of the screening protocols used by interprofessional members of the healthcare team is necessary to determine patient safety and risk mitigation.
Authors: Crystal Blakely, RN, BScN, CCN(c)), Debra Campbell, RN, BScN, CCN(c), Fioretta Bouchard, RN, Reg Hart, RN, BA, Jessica Mangan, RN, BScN, and Lisa Smith, RN, BScN
Cardiac rhythm devices have become an essential component in the treatment of arrhythmias, heart failure and advanced cardiovascular disease. This patient population is growing due to the expanding clinical indications for device therapy. Inevitably, device patients will be faced with end of life decisions regardless of their underlying medical condition. Evidently, interprofessionals will be exposed to this patient population and will require modification to their care plans based on current guidelines. Practitioners need to be aware of the principles of device therapy, clinical indications for patient specific therapy, the ethical and legal dilemmas associated with device deactivation and the process of deactivation itself.
Our objective was to develop a collaborative clinical education tool that could be used by nurse educators and interprofessionals as a reference when caring for device patients at end of life. The tool combines a variety of adult learning principles and strategies and uses information based on current guidelines and evidence-based practice.
The goal is to provide the necessary education for interprofessionals to provide high quality patient care to device patients at end of life and to disseminate this information as a quick reference resource available on all units when clinical experts are not readily available. We plan to trial the tool within our institution, collect feedback and if the response is positive, to share this tool with our regional hospitals and long term care facilities.